Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors

25 May 2024

Abstract excerpt

Homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitor (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score (GIS) threshold of ≥ 42 is a valid biomarker to predict response to PARPi in patients with ovarian cancer and breast cancer. However, the GIS threshold for prostate cancer (PCa) is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39281716
DOI: 10.1016/j.jncc.2024.05.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitorsPMID 39281716Read ↗

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate CarcinomasSemantic proximity Read ↗

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read ↗

Clinical implications of homologous recombination repair mutations in prostate cancer.Semantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate CancerSemantic proximity Read ↗

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read ↗

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsSemantic proximity Read ↗

Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.